Endoplasmic Reticulum Stress Regulators : New Drug Targets for Parkinson's Disease

Show full item record




Kovaleva , V & Saarma , M 2021 , ' Endoplasmic Reticulum Stress Regulators : New Drug Targets for Parkinson's Disease ' , Journal of Parkinson's disease , vol. 11 , no. s2 , pp. S219-S228 . https://doi.org/10.3233/jpd-212673

Title: Endoplasmic Reticulum Stress Regulators : New Drug Targets for Parkinson's Disease
Author: Kovaleva, Vera; Saarma, Mart
Contributor organization: Institute of Biotechnology
Mart Saarma / Principal Investigator
Date: 2021
Language: eng
Number of pages: 10
Belongs to series: Journal of Parkinson's disease
ISSN: 1877-7171
DOI: https://doi.org/10.3233/jpd-212673
URI: http://hdl.handle.net/10138/335297
Abstract: Parkinson's disease (PD) pathology involves progressive degeneration and death of vulnerable dopamine neurons in the substantia nigra. Extensive axonal arborization and distinct functions make this type of neurons particularly sensitive to homeostatic perturbations, such as protein misfolding and Ca2+ dysregulation. Endoplasmic reticulum (ER) is a cell compartment orchestrating protein synthesis and folding, as well as synthesis of lipids and maintenance of Ca2+ homeostasis in eukaryotic cells. When misfolded proteins start to accumulate in ER lumen the unfolded protein response (UPR) is activated. UPR is an adaptive signaling machinery aimed at relieving of protein folding load in the ER. When UPR is chronic, it can either boost neurodegeneration and apoptosis or cause neuronal dysfunctions. We have recently discovered that mesencephalic astrocyte-derived neurotrophic factor (MANF) exerts its prosurvival action in dopamine neurons and in an animal model of PD through the direct binding to UPR sensor inositol-requiring protein 1 alpha (IRE1) and attenuation of UPR. In line with this, UPR targeting resulted in neuroprotection and neurorestoration in various preclinical animal models of PD. Therefore, growth factors (GFs), possessing both neurorestorative activity and restoration of protein folding capacity are attractive as drug candidates for PD treatment especially their blood-brain barrier penetrating analogs and small molecule mimetics. In this review, we discuss ER stress as a therapeutic target to treat PD; we summarize the existing preclinical data on the regulation of ER stress for PD treatment. In addition, we point out the crucial aspects for successful clinical translation of UPR-regulating GFs and new prospective in GFs-based treatments of PD, focusing on ER stress regulation.
Description: Publisher Copyright: © 2021 - The authors. Published by IOS Press.
Subject: 3112 Neurosciences
3124 Neurology and psychiatry
cerebral dopamine neurotrophic factor
endoplasmic reticulum stress
growth factors
mesencephalic astrocyte-derived neurotrophic factor
Parkinson's disease
unfolded protein response
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
jpd_2021_11_s2_ ... 12673_jpd_11_jpd212673.pdf 1.301Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record